135 related articles for article (PubMed ID: 17484896)
41. Synthesis and antiviral evaluation of ribavirin congeners containing a hexitol moiety.
Van Aerschot A; Schepers G; Busson R; Neyts J; De Clercq E; Herdewijn P
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):849-51. PubMed ID: 14565294
[TBL] [Abstract][Full Text] [Related]
42. Practical synthesis of a potent hepatitis C virus RNA replication inhibitor.
Bio MM; Xu F; Waters M; Williams JM; Savary KA; Cowden CJ; Yang C; Buck E; Song ZJ; Tschaen DM; Volante RP; Reamer RA; Grabowski EJ
J Org Chem; 2004 Sep; 69(19):6257-66. PubMed ID: 15357584
[TBL] [Abstract][Full Text] [Related]
43. Viral error catastrophe by mutagenic nucleosides.
Anderson JP; Daifuku R; Loeb LA
Annu Rev Microbiol; 2004; 58():183-205. PubMed ID: 15487935
[TBL] [Abstract][Full Text] [Related]
44. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin.
Crotty S; Andino R
Microbes Infect; 2002 Nov; 4(13):1301-7. PubMed ID: 12443894
[TBL] [Abstract][Full Text] [Related]
45. New treatment options for chronic hepatitis C.
van Soest H; van Hattum J
Adv Exp Med Biol; 2003; 531():219-26. PubMed ID: 12916794
[No Abstract] [Full Text] [Related]
46. Ribavirin's antiviral mechanism of action: lethal mutagenesis?
Crotty S; Cameron C; Andino R
J Mol Med (Berl); 2002 Feb; 80(2):86-95. PubMed ID: 11907645
[TBL] [Abstract][Full Text] [Related]
47. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection.
Grebely J; Matthews GV; Petoumenos K; Dore GJ
J Viral Hepat; 2010 Dec; 17(12):896. PubMed ID: 20051007
[No Abstract] [Full Text] [Related]
48. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity.
Pfeiffer JK; Kirkegaard K
Proc Natl Acad Sci U S A; 2003 Jun; 100(12):7289-94. PubMed ID: 12754380
[TBL] [Abstract][Full Text] [Related]
49. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia.
Giannini C; Petrarca A; Monti M; Arena U; Caini P; Solazzo V; Gragnani L; Milani S; Laffi G; Zignego AL
Blood; 2008 Mar; 111(5):2943-5. PubMed ID: 18299456
[No Abstract] [Full Text] [Related]
50. Hepatitis C position statement: Taking a stand and standing by it.
Sanai FM; Alghamdi AS; Alghamdi MY
Saudi J Gastroenterol; 2015; 21(4):262-3. PubMed ID: 26228373
[No Abstract] [Full Text] [Related]
51. Quasispecies, error catastrophe, and the antiviral activity of ribavirin.
Graci JD; Cameron CE
Virology; 2002 Jul; 298(2):175-80. PubMed ID: 12127780
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis C: a new horizon.
Chang KM
Gastroenterology; 2006 Dec; 131(6):1667-8. PubMed ID: 17188957
[No Abstract] [Full Text] [Related]
53. New antiviral therapies for hepatitis C.
O'Leary J; Chung RT
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):265-74. PubMed ID: 14695693
[No Abstract] [Full Text] [Related]
54. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Harrington PR; Deming DJ; Komatsu TE; Naeger LK
Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
[No Abstract] [Full Text] [Related]
55. The application and mechanism of action of ribavirin in therapy of hepatitis C.
Thomas E; Ghany MG; Liang TJ
Antivir Chem Chemother; 2012 Sep; 23(1):1-12. PubMed ID: 22592135
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future.
Wong JB
Hepatology; 2002 Jul; 36(1):252-4. PubMed ID: 12085373
[No Abstract] [Full Text] [Related]
57. Hepatitis C drug being developed.
AIDS Patient Care STDS; 2004 Jan; 18(1):62. PubMed ID: 15080102
[No Abstract] [Full Text] [Related]
58. Gumming up the works: DNA polymers as HCV entry inhibitors.
Counihan NA; Lindenbach BD
Gastroenterology; 2009 Aug; 137(2):427-30. PubMed ID: 19563837
[No Abstract] [Full Text] [Related]
59. Genetic antiviral program against hepatitis C virus.
Sivov IG; Samokhvalov EI; Knyazhev VA
Dokl Biochem Biophys; 2003; 392():288-91. PubMed ID: 15255205
[No Abstract] [Full Text] [Related]
60. Miravirsen works against hepatitis C virus.
BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
